Advaxis

Notes

Advaxis (Nasdaq: ADXS) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of immunotherapies for cancer and infectious diseases. The company's proprietary ADXS platform uses live attenuated Listeria monocytogenes bacteria bioengineered to secrete antigen/adjuvant fusion proteins to stimulate anti-tumor immune responses.

The Lm Technology platform has been shown to activate both innate and adaptive immunity while reducing immunosuppression in the tumor microenvironment.

Team

• Kenneth Berlin - Former President & CEO
• Andres Gutierrez, M.D., Ph.D. - Former Chief Medical Officer

Additional Research Findings

• Portfolio company of aMoon
• Publicly traded on Nasdaq (ticker: ADXS)
• Lead programs focused on HPV-associated cancers
• ADXS-NEO platform for personalized neoantigen-based immunotherapy
• Collaborations with major pharmaceutical companies
• Multiple clinical trials conducted across various cancer indications
• Technology based on research from University of Pennsylvania

Sources

• Advaxis Official Website
• Advaxis LinkedIn
• Nasdaq: ADXS
• SEC Filings